Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment

References

• De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016 Jul;29(3):695–747.
   Google Scholar
• De Clercq E. A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol. 2011;51:1–24.
   Google Scholar
• De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers. 2004. 1. 1(1):44–64.
   Google Scholar
• Namasivayam V, Vanangamudi M, Kramer VG, et al. The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic. J Med Chem. 2019 May 23;62(10):4851–4883.
   Google Scholar
• Das K, Martinez SE, DeStefano JJ, et al. Structure of HIV-1 RT/dsRNA initiation complex prior to nucleotide incorporation. Proc Natl Acad Sci U S A. 2019 Apr 9;116(15):7308–7313.
   Google Scholar
• Das K, Arnold E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. Curr Opin Virol. 2013 Apr;3(2):119–128.
   Google Scholar
• London RE. HIV-1 reverse transcriptase: a metamorphic protein with three stable states. Structure. 2019 Mar 5;27(3):420–426.
   Google Scholar
• Das K, Arnold E. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr Opin Virol. 2013 Apr;3(2):111–118.
   Google Scholar
• Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 2008 Jun;134(1–2):147–156.
   Google Scholar
• Li G, Piampongsant S, Faria NR, et al. An integrated map of HIV genome-wide variation from a population perspective. Retrovirology. 2015 Feb;15(12):18.
   Google Scholar
• Li G, De Clercq E. HIV genome-wide protein associations: a review of 30 years of research. Microbiol Mol Biol Rev. 2016 Sep;80(3):679–731.
   Google Scholar
• Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. Update of the drug resistance mutations in HIV-1. 2019 Jul–Aug:27(3).
   Google Scholar
• Lai MT, Munshi V, Lu M, et al. Mechanistic study of common non-nucleoside reverse transcriptase inhibitor-resistant mutations with K103N and Y181C substitutions. Viruses. 2016 Sep 23;8:10.
   Google Scholar
• Lai MT, Feng M, Falgueyret JP, et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58(3):1652–1663.
   Google Scholar
• Li D, Zhan P, De Clercq E, et al. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms. J Med Chem. 2012 Apr 26;55(8):3595–3613.
   Google Scholar
• Vanangamudi M, Poongavanam V, Namasivayam V. HIV-1 non-nucleoside reverse transcriptase inhibitors: SAR and lead optimization using CoMFA and CoMSIA studies (1995–2016). Curr Med Chem. 2017 Nov 17;24(34):3774–3812.
   Google Scholar
• Gutierrez-Valencia A, Martin-Pena R, Torres-Cornejo A, et al. Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients. J Antimicrob Chemother. 2012 Mar;67(3):681–684.
   Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004 Jul 14;292(2):191–201.
   Google Scholar
• Orkin C, Arastéh K, Hernández-Mora MG, et al. Long-acting cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results. In: CROI 2019. Seattle; 2019 Mar 4–7.
   Google Scholar
• Swindells S, Andrade-Villanueva J,J, Richmond G, et al. Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week 48 results. In: CROI 2019. Seattle; 2019 Mar 4–7.
   Google Scholar
• Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004 Dec;48(12):4680–4686.
   Google Scholar
• Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999 Aug;27(8):895–901.
   Google Scholar
• Lange JM. Efficacy and durability of nevirapine in antiretroviral drug naive patients. J Acquir Immune Defic Syndr. 2003 Sep;34(Suppl 1):S40–52.
   Google Scholar
• Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998 Mar 25;279(12):930–937.
   Google Scholar
• Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN trial. Antivir Ther. 2011;16(3):339–348.
   Google Scholar
• Gathe J, Andrade-Villanueva J, Santiago S, et al. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Antivir Ther. 2011;16(5):759–769.
   Google Scholar
• Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2013 Jun 1;27(9):1403–1412.
   Google Scholar
• Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. April. 2002. IAPAC Mon. 2002 Jun;8(6):168–175.
   Google Scholar
• Scott LJ, Perry CM. Delavirdine: a review of its use in HIV infection. Drugs. 2000 Dec;60(6):1411–1444.
   Google Scholar
• Morse GD, Fischl MA, Shelton MJ, et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1997 Jan;41(1):169–174.
   Google Scholar
• Pagano PJ, Chong KT. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. J Infect Dis. 1995 Jan;171(1):61–67.
   Google Scholar
• Dalwadi DA, Ozuna L, Harvey BH, et al. Adverse neuropsychiatric events and recreational use of efavirenz and other HIV-1 antiretroviral drugs. Pharmacol Rev. 2018 Jul;70(3):684–711.
   Google Scholar
• Adkins JC, Noble S. Efavirenz. Drugs. 1998 Dec;56(6):1055–1064. discussion 1065-6.
   Google Scholar
• Vrouenraets SM, Wit FW, van Tongeren J, et al. Efavirenz: a review. Expert Opin Pharmacother. 2007 Apr;8(6):851–871.
   Google Scholar
• Albrecht MA, Bosch RJ, Hammer SM, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med. 2001 Aug 9;345(6):398–407.
   Google Scholar
• Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 team. N Engl J Med. 1999 Dec 16;341(25):1865–1873.
   Google Scholar
• Initio Trial International Co-ordinating Committee. Virological and immunological outcomes at. 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet. 2006 Jul 22;368(9532):287–298.
   Google Scholar
• Pillay P, Ford N, Shubber Z, et al. Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS One. 2013;8(7):e68995.
   Google Scholar
• Encore Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015 Jul;15(7):793–802.
   Google Scholar
• Encore Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014 Apr 26;383(9927):1474–1482.
   Google Scholar
• Boffito M, Lamorde M, Watkins M, et al. Antiretroviral dose optimization: the future of efavirenz 400 mg dosing. Curr Opin HIV AIDS. 2017 Jul;12(4):339–342.
   Google Scholar
• Apostolova N, Funes HA, Blas-Garcia A, et al. Efavirenz and the CNS: what we already know and questions that need to be answered. J Antimicrob Chemother. 2015 Oct;70(10):2693–2708.
   Google Scholar
• Usach I, Melis V, Peris JE. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc. 2013 Sep;4(16):1–14.
   Google Scholar
• Scholler-Gyure M, Kakuda TN, Raoof A, et al. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48(9):561–574.
   Google Scholar
• Deeks ED, Keating GM. Etravirine. Drugs. 2008;68(16):2357–2372.
   Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 7;370(9581):39–48.
   Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 Jul 7;370(9581):29–38.
   Google Scholar
• Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009 Nov 13;23(17):2289–2300.
   Google Scholar
• Gazzard B, Duvivier C, Zagler C, et al. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS. 2011 Nov 28;25(18):2249–2258.
   Google Scholar
• Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009 Nov 1;49(9):1441–1449.
   Google Scholar
• Katlama C, Assoumou L, Valantin MA, et al. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the phase II ANRS 163 ETRAL study. J Antimicrob Chemother. 2019 Sep 1;74(9):2742–2751.
   Google Scholar
• Tudor-Williams G, Cahn P, Chokephaibulkit K, et al. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. HIV Med. 2014 Oct;15(9):513–524.
   Google Scholar
• Basson AE, Rhee SY, Parry CM, et al. Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2015 Feb;59(2):960–971.
   Google Scholar
• Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS. 2010 Feb 20;24(4):503–514.
   Google Scholar
• Girard PM, Campbell TB, Grinsztejn B, et al. Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest. HIV Med. 2012 Aug;13(7):427–435.
   Google Scholar
• Garvey L, Winston A. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs. 2009 Jul;18(7):1035–1041.
   Google Scholar
• Fernandez-Montero JV, Vispo E, Anta L, et al. Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. Expert Opin Pharmacother. 2012 May;13(7):1007–1014.
   Google Scholar
• Mordant C, Schmitt B, Pasquier E, et al. Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. Eur J Med Chem. 2007 May;42(5):567–579.
   Google Scholar
• Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010 Feb;54(2):718–727.
   Google Scholar
• Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011 Jul 16;378(9787):238–246.
   Google Scholar
• Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011 Jul 16;378(9787):229–237.
   Google Scholar
• Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS. 2013 Mar 27;27(6):939–950.
   Google Scholar
• Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 May;4(5):e195–e204.
   Google Scholar
• DeJesus E, Ramgopal M, Crofoot G, et al. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 May;4(5):e205–e213.
   Google Scholar
• Hagins D, Orkin C, Daar ES, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018 Nov;19(10):724–733.
   Google Scholar
• Petchkum P, Sungkanuparph S, Kiertiburanakul S, et al. Efficacy of rilpivirine-based regimens as switch therapy from nevirapine-based regimens in human immunodeficiency virus-infected patients with virological suppression: a randomized controlled trial. Open Forum Infect Dis. 2019 Apr;6(4):ofz155.
   Google Scholar
• Behrens G, Rijnders B, Nelson M, et al. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA </=100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS. 2014 Apr;28(4):168–175.
   Google Scholar
• Rhee SY, Blanco JL, Jordan MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015 Apr;12(4):e1001810.
   Google Scholar
• Colombier MA, Molina JM. Doravirine: a review. Curr Opin HIV AIDS. 2018 Jul;13(4):308–314.
   Google Scholar
• Feng M, Sachs NA, Xu M, et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016 Apr;60(4):2241–2247.
   Google Scholar
• Anderson MS, Gilmartin J, Cilissen C, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20(4):397–405.
   Google Scholar
• Sanchez RI, Fillgrove KL, Yee KL, et al. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019 Apr;49(4):422–432.
   Google Scholar
• Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019 Feb 1;68(4):535–544.
   Google Scholar
• Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018 May;5(5):e211–e220.
   Google Scholar
• Johnson M, Kumar P, Molina JM, et al. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):463–472.
   Google Scholar
• Feng M, Wang D, Grobler JA, et al. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015 Jan;59(1):590–598.
   Google Scholar
• Al-Salama ZT. Elsulfavirine: first global approval. Drugs. 2017 Oct;77(16):1811–1816.
   Google Scholar
• Ratanasuwan W, Werarak P, Koryakova A, et al. Parmacokinetics of VM-1500 20 mg and 40 mg in healthy and HIV-infected patients. In: 20st International AIDS Conference. Melbourne; 2014.
   Google Scholar
• Murphy R, Kravchenko AV, Orlova-Morozova E, et al. Elsulfavirine as compared to efavirenz in combination with TDF/FTC: 48-week study. In: CROI 2017. Seattle; 2017 Feb 13–16.
   Google Scholar
• Margolis DA, Eron JJ, DeJesus E, et al. Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the phase IIb evaluation of fosdevirine (GSK2248761). Antivir Ther. 2014;19(1):69–78.
   Google Scholar
• DeJesus E, Fatkenheuer G, Orrell C, et al. Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial. HIV Clin Trials. 2014 Sep–Oct;15(5):209–217.
   Google Scholar
• Das Neves J, Martins JP, Sarmento B. Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing. Adv Drug Deliv Rev. 2016 Aug 1;103:20–32.
   Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016 Dec 1;375(22):2121–2132.
   Google Scholar
• Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016 Dec 1;375(22):2133–2143.
   Google Scholar
• Pereira LE, Singletary T, Martin A, et al. Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques. Drug Deliv Transl Res. 2018 Oct;8(5):1180–1190.
   Google Scholar
• Ham AS, Nugent ST, Peters JJ, et al. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. Antiviral Res. 2015;120:153–164.
   Google Scholar
• Pereira LE, Mesquita PM, Ham A, et al. Pharmacokinetic and pharmacodynamic evaluation following vaginal application of IQB3002, a dual-chamber microbicide gel containing the nonnucleoside reverse transcriptase inhibitor IQP-0528 in rhesus macaques. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1393–1400.
   Google Scholar
• Friedland BA, Hoesley CJ, Plagianos M, et al. First-in-human trial of MIV-150 and zinc acetate coformulated in a carrageenan gel: safety, pharmacokinetics, acceptability, adherence, and pharmacodynamics. J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):489–496.
   Google Scholar
• Huang B, Chen W, Zhao T, et al. Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket: discovery of potent diarylpyrimidine-typed HIV-1 NNRTIs against wild-type and E138K mutant virus with significantly improved water solubility and favorable safety profiles. J Med Chem. 2019 Feb 28;62(4):2083–2098.
   Google Scholar
• Kudalkar SN, Beloor J, Quijano E, et al. From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E802–E811.
   Google Scholar
• Kudalkar SN, Beloor J, Chan AH, et al. Structural and preclinical studies of computationally designed non-nucleoside reverse transcriptase inhibitors for treating HIV infection. Mol Pharmacol. 2017 Apr;91(4):383–391.
   Google Scholar
• Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, et al. Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf. 2017 Aug;16(8):923–932.
   Google Scholar
• Dolgin E. Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med. 2014 Apr;20(4):323–324.
   Google Scholar
• Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018 Mar 3;391(10123):839–849.
   Google Scholar
• Capetti AF, Cossu MV, Sterrantino G, et al. Dolutegravir plus rilpivirine as a switch option in cART-experienced patients: 96-week data. Ann Pharmacother. 2018 Aug;52(8):740–746.
   Google Scholar
• Sun HY, Chang SY, Hung CC. Dolutegravir-rilpivirine coformulation. Curr Opin HIV AIDS. 2018 Jul;13(4):320–325.
   Google Scholar
• Joly V, Burdet C, Landman R, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019 Mar 1;74(3):739–745.
   Google Scholar
• Jablonowska E, Siwak E, Bociaga-Jasik M, et al. Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. PloS One. 2019;14(1):e0210476.
   Google Scholar
• Pasquau J, de Jesus SE, Arazo P, et al. Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study). BMC Infect Dis. 2019 Feb 28;19(1):207.
   Google Scholar
• Corado KC, Caplan MR, Daar ES. Two-drug regimens for treatment of naive HIV-1 infection and as maintenance therapy. Drug Des Devel Ther. 2018;12:3731–3740.
   Google Scholar
• Gulick RM, Flexner C. Long-acting HIV drugs for treatment and prevention. Annu Rev Med. 2019 Jan;27(70):137–150.
   Google Scholar
• Williams PE, Crauwels HM, Basstanie ED, Formulation and pharmacology of long-acting rilpivirine. Curr Opin HIV AIDS. 2015 Jul; 10(4):233–238
   Google Scholar
• MTC MC, Larraneta E, Clark A, et al. Design, formulation, and evaluation of novel dissolving microarray patches containing rilpivirine for intravaginal delivery. Adv Healthc Mater. 2019 May;8(9):e1801510.
   Google Scholar
• MTC MC, Larraneta E, Clark A, et al. Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension. J Control Release. 2018 Dec;28(292):119–129.
   Google Scholar
• Verloes R, Deleu S, Niemeijer N, et al. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. HIV Med. 2015 Sep;16(8):477–484.
   Google Scholar
• McGowan I, Dezzutti CS, Siegel A, et al. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. Lancet HIV. 2016 Dec;3(12):e569–e578.
   Google Scholar
• Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017 Sep 23;390(10101):1499–1510.
   Google Scholar
• Battini L, Bollini M. Challenges and approaches in the discovery of human immunodeficiency virus type-1 non-nucleoside reverse transcriptase inhibitors. Med Res Rev. 2019 Jul;39(4):1235–1273.
   Google Scholar
• Sebaaly JC, Kelley D, Clinical Updates: HIV. New single-tablet regimens. Ann Pharmacother. 2019 Jan;53(1):82–94.
   Google Scholar
• MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet. 2006 Dec 16;368(9553):2125–2135.
   Google Scholar
• Chou R, Fu R, Huffman LH, et al. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet. 2006 Oct 28;368(9546):1503–1515.
   Google Scholar
• Borges AH, Lundh A, Tendal B, et al. Nonnucleoside reverse-transcriptase inhibitor- vs ritonavir-boosted protease inhibitor-based regimens for initial treatment of HIV infection: a systematic review and metaanalysis of randomized trials. Clin Infect Dis. 2016 Jul 15;63(2):268–280.
   Google Scholar
• Jespersen S, Honge BL, Krarup H, et al. Protease inhibitors or NNRTIs as first-line HIV-1 treatment in West Africa (PIONA): a randomized controlled trial. J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):386–393.
   Google Scholar
• Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naive human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study. Medicine (Baltimore). 2018 Oct;97(43):e13016.
   Google Scholar
• Calmy A, Tarr PE. Will NNRTIs be driving forward again? Lancet HIV. 2018 May;5(5):e200–e201.
   Google Scholar
• Hofstra LM, Sauvageot N, Albert J, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016 Mar 1;62(5):655–663.
   Google Scholar
• Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018 Mar;18(3):346–355.
   Google Scholar
• Jordan MR, Penazzato M, Cournil A, et al. Human immunodeficiency virus (HIV) drug resistance in african infants and young children newly diagnosed with HIV: a multicountry analysis. Clin Infect Dis. 2017 Nov 29;65(12):2018–2025.
   Google Scholar
• Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012 Jun 18;72(9):e1–25.
   Google Scholar
• Bruccoleri A. Positional adaptability in the design of mutation-resistant nonnucleoside HIV-1 reverse transcriptase inhibitors: a supramolecular perspective. AIDS Res Hum Retroviruses. 2013 Jan;29(1):4–12.
   Google Scholar
• La Regina G, Coluccia A, Silvestri R. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors. Antivir Chem Chemother. 2010 Aug 11;20(6):213–237.
   Google Scholar
• Huo Z, Zhang H, Kang D, et al. Discovery of novel diarylpyrimidine derivatives as potent HIV-1 NNRTIs targeting the “NNRTI Adjacent” binding site. ACS Med Chem Lett. 2018 Apr 12;9(4):334–338.
   Google Scholar
• Kang D, Wang Z, Zhang H, et al. Further exploring solvent-exposed tolerant regions of allosteric binding pocket for novel HIV-1 NNRTIs discovery. ACS Med Chem Lett. 2018 Apr 12;9(4):370–375.
   Google Scholar
• Sluis-Cremer N. Future of nonnucleoside reverse transcriptase inhibitors. Proc Natl Acad Sci U S A. 2018 Jan 23; 115(4):637–638.
   Google Scholar